Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan Plans To Beef Up Drug Safety

This article was originally published in PharmAsia News

Executive Summary

TOKYO - In an effort to better align its drug safety standards with the U.S. and Europe, Japan's Ministry of Health, Labour and Welfare is proposing to drastically increase the manpower dedicated to investigating adverse events of marketed drugs

You may also be interested in...



Device Manufacturers Negotiate With Japan For Higher User Fees To Speed Review

By April 1 of next year the number of medical device reviewers in Japan could increase dramatically via a substantial raise in industry-paid user fees

Device Manufacturers Negotiate With Japan For Higher User Fees To Speed Review

By April 1 of next year the number of medical device reviewers in Japan could increase dramatically via a substantial raise in industry-paid user fees

Japan Survey Finds 10 Percent Given Fibrinogen Contracted HCV

Japan's health ministry reports a recent survey found 10 percent of patients who received a Green Cross version of fibrinogen became infected with hepatitis C. The suspect batch of the blood thinner was traced back to Green Cross, a predecessor of Mitsubishi Tanabe Pharma. Fibrinogen is an adhesive used during surgery and as a hemostat agent in operations. The ministry said its survey found that of 7,406 patients administered the drug, 741 contracted hepatitis C, and experts expect the total to rise as the investigation continues. (Click here for more

UsernamePublicRestriction

Register

LL1130096

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel